Rakuten Medical Initiates First-in-Human Phase 1 Clinical Trial of RM-0256 in Japan
· GlobeWire Daily Business Desk · Source: www.prnewswire.com

Image: Rakuten Medical, Inc. · Photo source · Resized and letterboxed to 16:9; no AI generation
Overview of the Phase 1 Study
Rakuten Medical has officially initiated a first-in-human Phase 1 clinical trial (jRCT2031260118) in Japan for its new photoimmunotherapy candidate, RM-0256. This investigational therapy is designed to target PD-L1-expressing cells through the company's proprietary Alluminox platform.
Study Details and Objectives
The open-label, dose-escalation study aims to enroll 24 patients with solid tumors, specifically targeting malignant epithelial skin tumors that have not responded to standard treatments. The primary goals of the trial include:
- Evaluating the safety and tolerability of the RM-0256 therapy.
- Determining optimal drug and light dosage levels for future Phase 2 development.
- Assessing dose-limiting toxicities and adverse events.
The trial is currently being conducted at three major medical facilities in Japan: Kobe University Hospital, the National Cancer Center Hospital, and the National Cancer Center Hospital East. Funding for this research is provided by the Japan Agency for Medical Research and Development (AMED).
Understanding the Technology
RM-0256 consists of an anti-PD-L1 antibody conjugated to a light-activatable dye, IRDye 700DX (IR700). The treatment process involves an intravenous infusion followed approximately 24 hours later by illumination of the targeted site with 690 nm laser light. Preclinical data suggests that the therapy may function through three mechanisms:
- Direct destruction of tumor cells expressing PD-L1.
- Elimination of immunosuppressive cells within the tumor microenvironment.
- Inhibition of the PD-L1/PD-1 interaction to support antitumor immune responses.
Interested parties can verify trial details via the Japan Registry of Clinical Trials (jRCT).
AI-assisted reporting; source claims are attributed and have not been independently verified.



